ADA Scientific Sessions 2026 Abstract

Efficacy and Safety of DA-302168S, a Novel Oral GLP-1 Receptor Agonist, in Chinese Adults with Overweight or Obesity: A Phase 2 Trial

By Linong Ji, Yingying Luo, Guangxin Dong, Zhou Yu

Trial in peopleInterventions

The paper

Linong Ji, Yingying Luo, Guangxin Dong, Zhou Yu

Beijing

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 2608-P

doi.org/10.2337/db26-2608-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety